1887

Abstract

Human immunodeficiency virus type 1 (HIV-1) subtype C is the predominant HIV in southern Africa, and is the target of a number of recent vaccine candidates. It has been proposed that a heterologous prime/boost vaccination strategy may result in stronger, broader and more prolonged immune responses. Since HIV-1 Gag Pr55 polyprotein can assemble into virus-like particles (VLPs) which have been shown to induce a strong cellular immune response in animals, we showed that a typical southern African subtype C Pr55 protein expressed in insect cells via recombinant baculovirus could form VLPs. We then used the baculovirus-produced VLPs as a boost to a subtype C HIV-1 DNA prime vaccination in mice. This study shows that a low dose of HIV-1 subtype C Gag VLPs can significantly boost the immune response to a single subtype C DNA inoculation in mice. These results suggest a possible vaccination regimen for humans.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.19396-0
2004-02-01
2019-11-12
Loading full text...

Full text loading...

/deliver/fulltext/jgv/85/2/vir850409.html?itemId=/content/journal/jgv/10.1099/vir.0.19396-0&mimeType=html&fmt=ahah

References

  1. Addo, M. M., Yu, X. G., Rathod, A. and 17 other authors ( 2003; ). Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol 77, 2081–2092.[CrossRef]
    [Google Scholar]
  2. Amara, R. R., Villlinger, F., Altman, J. D. & 19 other authors ( 2001; ). Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292, 69–74.[CrossRef]
    [Google Scholar]
  3. Barouch, D. H., Craiu, A., Kuroda, M. J. & 19 other authors ( 2000; ). Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. Proc Natl Acad Sci U S A 97, 4192–4197.[CrossRef]
    [Google Scholar]
  4. Bojak, A., Deml, L. & Wagner, R. ( 2002; ). The past, present and future of HIV-vaccine development: a critical view. Drug Discov Today 7, 36–46.[CrossRef]
    [Google Scholar]
  5. Buonaguro, L., Buonaguro, F. M., Tornesello, M. L. & 7 other authors ( 2001; ). High efficient production of Pr55 gag virus-like particles expressing multiple HIV-1 epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A. Antivir Res 49, 35–47.[CrossRef]
    [Google Scholar]
  6. Freed, E. O. ( 1998; ). HIV-1 Gag proteins: diverse functions in the virus life cycle. Virology 251, 1–15.[CrossRef]
    [Google Scholar]
  7. Gaschen, B., Taylor, J., Yusim, K. & 8 other authors ( 2002; ). Diversity considerations in HIV-1 vaccine selection. Science 296, 2354–2360.[CrossRef]
    [Google Scholar]
  8. Gheysen, D., Jacobs, E., de Forests, F., Thiriart, C., Francotte, M., Thines, D. & De Wilde, M. ( 1989; ). Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected cells. Cell 59, 103–112.[CrossRef]
    [Google Scholar]
  9. Haglund, K., Leiner, I., Kerksiek, K., Buonocore, L., Pamer, E. & Rose, J. K. ( 2002; ). Robust recall and long-term memory T-cell responses induced by prime-boost regimens with heterologous live viral vectors expressing human immunodeficiency virus type 1 Gag and Environ proteins. J Virol 76, 7506–7517.[CrossRef]
    [Google Scholar]
  10. Huang, Y., Kong, W.-P. & Nabel, G. J. ( 2001; ). Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression. J Virol 75, 4947–4951.[CrossRef]
    [Google Scholar]
  11. Jowett, J. B. M., Hockley, D. J., Nermut, M. V. & Jones, J. M. ( 1992; ). Distinct signals in human immunodeficiency virus type 1 Pr55 necessary for RNA binding and particle formation. J Gen Virol 73, 3079–3086.[CrossRef]
    [Google Scholar]
  12. McMichael, A., Mwau, M. & Hanke, T. ( 2002; ). HIV T cell vaccines, the importance of clades. Vaccine 20, 1918–1921.[CrossRef]
    [Google Scholar]
  13. Mergener, K., Fäcke, M., Welker, R., Brinkmann, V., Gelderblom, H. R. & Kräusslich, H.-G. ( 1992; ). Analysis of HIV particle formation using transient expression of subviral constructs in mammalian cells. Virology 186, 25–39.[CrossRef]
    [Google Scholar]
  14. Mwau, M. & McMichael, A. J. ( 2003; ). A review of vaccines for HIV prevention. J Gene Med 5, 3–10.[CrossRef]
    [Google Scholar]
  15. Nabel, G. J. ( 2002; ). HIV vaccine strategies. Vaccine 20, 1945–1947.[CrossRef]
    [Google Scholar]
  16. Nermut, M. V., Hockley, D. J., Jowett, J. B. M., Jones, I. M., Garreau, M. & Thomas, D. ( 1994; ). Fullerene-like organization of HIV Gag-protein shell in virus-like particles produced by recombinant baculovirus. Virology 198, 288–296.[CrossRef]
    [Google Scholar]
  17. Nermut, M. V., Zhang, W.-H., Francis, G., Ciampor, F., Morikawa, Y. & Jones, I. M. ( 2003; ). Time course of Gag protein assembly in HIV-1-infected cells: a study by immunoelectron microscopy. Virology 305, 219–227.[CrossRef]
    [Google Scholar]
  18. Novitsky, V., Cao, H., Rybak, N. & 9 other authors ( 2002; ). Magnitude and frequency of cytotoxic T-lymphocyte responses: identification of immunodominant regions of human immunodeficiency virus type 1 subtype C. J Virol 76, 10155–10168.[CrossRef]
    [Google Scholar]
  19. Overton, H. A., Fuji, Y., Price, I. R. & Jones, I. M. ( 1989; ). The protease and gag gene products of the human immunodeficiency virus: authentic cleavage and post-translational modification in an insect cell expression system. Virology 170, 107–116.[CrossRef]
    [Google Scholar]
  20. Robinson, H. L., Montefiori, D. C., Johnson, P. R. P. & 14 other authors ( 1999; ). Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat Med 5, 526–534.[CrossRef]
    [Google Scholar]
  21. Royer, M., Cerutti, M., Gay, B., Hong, S.-S., Devauchelle, G. & Boulanger, P. ( 1991; ). Functional domain of HIV-1 Gag polyprotein expressed in baculovirus-infected cells. Virology 184, 417–422.[CrossRef]
    [Google Scholar]
  22. Royer, M., Hong, S.-S., Gray, V., Cerutti, M. & Boulanger, P. ( 1992; ). Expression and extracellular release of human immunodeficiency virus type 1 Gag precursors by recombinant baculovirus-infected cells. J Virol 66, 3230–3235.
    [Google Scholar]
  23. Shioda, T. & Shibuta, H. ( 1990; ). Production of human immunodeficiency virus (HIV)-like particles from cells infected with recombinant vaccinia viruses carrying the gag gene of HIV. Virology 175, 139–148.[CrossRef]
    [Google Scholar]
  24. Shiver, J. W., Fu, T.-M., Chen, L. & 49 other authors ( 2002; ). Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415, 331–335.[CrossRef]
    [Google Scholar]
  25. UNAIDS ( 2002; ). AIDS Epidemic Update December 2002. http://www.unaids.org/worldaidsday/2002/press/Epiupdate.html
  26. Vajdy, M., Gardner, J., Neidleman, J., Guadra, L., Greer, C., Perri, S. O'Hagan D. & Polo, J. M. ( 2001; ). Human immunodeficiency virus type 1 Gag-specific vagina immunity and protection after local immunizations with sindbis virus-based replicon particles. J Infect Dis 184, 1613–1616.[CrossRef]
    [Google Scholar]
  27. van Baalen, C. A., Klein, M. R., Huisman, R. C. & 7 other authors ( 1996; ). Fine specificity of cytotoxic T lymphocytes which recognize conserved epitopes of the Gag protein of human immunodeficiency virus type 1. J Gen Virol 77, 1659–1665.[CrossRef]
    [Google Scholar]
  28. van Harmelen, J. H., Shephard, E., Thomas, R., Hanke, T., Williamson, A.-L. & Williamson, C. ( 2003; ). Construction and characterisation of a candidate HIV-1 subtype C DNA vaccine for South Africa. Vaccine (in press).
    [Google Scholar]
  29. Vernon, S. K., Murthy, S., Wilhelm, J., Chanda, P. K., Kalyan, N., Lee, S.-G. & Hung, P. P. ( 1991; ). Ultrastructural characterization of human immunodeficiency virus type 1 Gag-containing particles assembled in a recombinant adenovirus vector system. J Gen Virol 72, 1243–1251.[CrossRef]
    [Google Scholar]
  30. Wee, E. G.-T., Patel, S., McMichael, J. & Hanke, T. ( 2002; ). A DNA/MVA-based candidate human immunodeficiency virus vaccine for Kenya induces multi-specific T cell responses in rhesus macaques. J Gen Virol 83, 75–80.
    [Google Scholar]
  31. Williamson, C., Morris, L., Maughan, M. F. & 12 other authors ( 2003; ). Characterization and selection of HIV-1 subtype C isolates for use in vaccine development. AIDS Res Hum Retrovir 19, 133–144.[CrossRef]
    [Google Scholar]
  32. Wills, J. W. & Craven, R. C. ( 1991; ). Form, function, and use of retroviral Gag proteins. AIDS 5, 639–654.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.19396-0
Loading
/content/journal/jgv/10.1099/vir.0.19396-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error